This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Agilent Technologies And Sera Prognostics Enter Strategic Partnership To Develop Proteomic Assays For Fetal And Maternal Health

Agilent Technologies Inc. (NYSE: A) and Sera Prognostics Inc., a women’s health company, today announced a strategic partnership to develop proteomic assays for the early prediction of pregnancy complications.

Sera Prognostics is currently developing a novel test for the early prediction of preterm birth risk using advanced proteomic science. Agilent is a leading provider of a wide range of analytical instrumentation, including liquid chromatography, mass spectrometry and automation systems.

“By providing pivotal information to physicians, Sera’s preterm birth predictor is designed to address an unmet medical need for a reliable, early risk assessment that has the potential to help significantly improve the health of mothers and newborns, while materially reducing the costs of care,” said Gregory C. Critchfield, M.D., M.S., chairman and chief executive officer of Sera Prognostics. “Our partnership with Agilent provides Sera with access to advanced and innovative technologies designed to deliver on the promise of personalized medicine.”

“Agilent and Sera Prognostics share the vision of applying the power of advanced proteomic technologies to address meaningful medical challenges,” said Yvonne Linney, VP and general manager of Agilent’s Life Science Solutions Division. “Agilent instrumentation is at the forefront of driving high-throughput workflows for sample preparation and mass-spec analysis that is critical in the field of proteomics.”

As part of the partnership, Sera Prognostics purchased multiple Agilent 1290 Infinity ultra high-performance liquid chromatography systems, 6490 iFunnel triple quadrupole mass spectrometry systems and 1260 Infinity LC systems with ultraviolet detectors and is adapting Agilent’s automated sample-preparation technologies for production.

The partners will develop high-throughput workflows for sample preparation and mass-spectrometry analysis. To meet the demands of high-volume testing, Sera Prognostics expects to leverage Agilent’s novel automated sample-prep technology and other automation, including the AssayMAP Bravo and RapidFire fast liquid chromatography together with ultra-sensitive ion funnel triple quadrupole mass spectrometry.

About Sera Prognostics, Inc.

Sera Prognostics is a private biotechnology company developing novel diagnostic tests designed for the early prediction of preterm birth and other pregnancy complications, so that personalized, effective care can be given. These innovative tests have the potential of improving the health of both mothers and infants. In November 2011, Sera completed a Series A financing round of $19.3 million to develop its ProNid preterm birth predictor. The company has assembled a strong management team and board of directors with significant clinical development and women's health-care diagnostic experience. Sera is currently completing the world’s largest clinical biomarker study focused on the validation of its ProNid test for predicting the risk of preterm birth. Sera is located in Salt Lake City, Utah. For more information, visit www.seraprognostics.com.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company’s 20,500 employees serve customers in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal 2012. Information about Agilent is available at www.agilent.com.

NOTE TO EDITORS: Further technology, corporate citizenship and executive news are available at www.agilent.com/go/news.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,705.59 -52.32 -0.29%
S&P 500 2,074.85 -2.57 -0.12%
NASDAQ 4,998.3880 -14.7350 -0.29%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs